



# MANAGEMENT OF TOBACCO USE AND DEPENDENCE

Regional Clinical Practice Guideline

## EVIDENCE INFORMED PRACTICE TOOLS

[www.wrha.mb.ca/professionals/ebpt/index.php](http://www.wrha.mb.ca/professionals/ebpt/index.php)

August, 2013

## Table of Contents

### Management of Tobacco Use and Dependence Regional Clinical Practice Guidelines

Authors - Regional Smoking Cessation Best Practice Working Group (SCBPWG).....	2
Background .....	3
Goals and Objectives of the Guideline .....	4
Target Population .....	4
Target Audience .....	4
Key Definitions .....	4
Guiding Principles .....	5
Methodology.....	6
How to Use This Guideline .....	6
Clinical Practice Guideline – Management of Tobacco Use and Dependence .....	7
Recommendations Specific to Acute Care .....	8
Recommendations for Systems Change and Clinical Education .....	9
Medication Recommendations .....	9
References .....	21
Appendix A .....	26

## Regional Smoking Cessation Best Practice Working Group (SCBPWG)

The following list identifies SCBPWG members who contributed to the development of this Clinical Practice Guideline, according to their position at the time of their contribution.

**Catherine Cook**, Vice President, Population and Aboriginal Health, WRHA (VP sponsor)  
**Lori Lamont**, Vice President and Chief Nursing Officer, WRHA (VP sponsor)  
**Caitlin Keyzer**, Chronic Disease Specialist, WRHA (SCBPWG Co-Facilitator)  
**Margie Kvern**, Program Specialist, Tobacco Reduction, WRHA (SCBPWG Co-Facilitator)  
**Annette Schultz**, Associate Professor, Faculty of Nursing, University of Manitoba  
**Beatrice Patton**, Patient Safety Pharmacist, WRHA  
**Betty Taylor**, Manager, PCH Infection Prevention & Control and Adult Day Program, WRHA  
**Bob McIlraith**, Program Director, Clinical Health Psychology, WRHA  
**Craig Hillier**, Regional Manager, Respiratory Therapy-Acute Care, WRHA  
**Diane Mee**, Public Health Coordinator, WRHA  
**Dianne Boyce**, Occupational Health Nurse, Seven Oaks Hospital  
**Jacqueline Nobiss**, Aboriginal Health Program, WRHA  
**Kathy Hamelin**, Clinical Nurse Specialist, Womens' Program, Health Sciences Centre  
**Kelly Langevin**, Manager, Communication and Public Affairs, WRHA  
**Kristine Petrasko**, Pulmonary Rehabilitation Educator, WRHA  
**Lorena Thiessen**, Perioperative Nurse Clinician, Victoria General Hospital  
**Lorraine Avery**, Regional Clinical Nurse Specialist, Cardiac Sciences Program, WRHA  
**Margaret Green**, Nurse Therapist, Adult Eating Disorders Program, Health Sciences Centre  
**Marlene Graceffo**, Program Director, Rehab and Geriatrics, WRHA  
**Mary Anne Lynch**, Program Director, Medicine, WRHA  
**Michael Routledge**, Medical Officer of Health, WRHA  
**Mike Daly**, Communications Specialist – Community, WRHA  
**Pat Honcharik**, Regional Pharmacy Manager, WRHA  
**Sande Harlos**, Medical Officer of Health, WRHA  
**Shannon Carpentier**, Health Promoter/Dietician, NorWest Co-op Community Health  
**Tira Sanderson**, Respiratory Case Coordinator, Respiratory Home Care, WRHA

**Michael Isaac**, Community Medicine Resident, WRHA (contributions to medication section)

## Background

Tobacco use continues to be a leading cause of death and disability in the Winnipeg Health Region (WHR). According to the Canadian Tobacco Use Monitoring Survey (CTUMS), 20.5% of Manitobans aged 15 years and older are current tobacco users<sup>1</sup>. According to the Winnipeg Regional Health Authority (WRHA) Community Health Assessment in 2009-10, 22.1% of our population aged 12 years and over are current smokers.<sup>2</sup> Half of long-term smokers will die from their tobacco use. This equates to approximately 1,400 deaths per year in Manitoba.<sup>3</sup>

Tobacco use is an even larger concern in a number of sub-populations, including people with mental health problems, people with low income/education, and people from First Nations, Inuit and Métis communities. People with mental health problems smoke at approximately 2.7 times the rate of the general population<sup>4,5</sup>, and consume close to half of the cigarettes smoked.<sup>4</sup> Canadians with less than high school education smoke at twice the rate of university graduates.<sup>6</sup> The First Nations and Inuit Health Branch of Health Canada reports that 59% of on-reserve First Nations people smoke.<sup>7</sup> A 2010 Manitoba Centre for Health Policy report, produced in collaboration with the Manitoba Métis Federation, found that the Métis population has a higher percentage of people who use tobacco (33.3%) compared to all other Manitobans (21.7%); this difference was found specifically among Winnipeg RHA residents as well (Metis-35.4%; all other WRHA residents-21.3%).<sup>8</sup>

In Manitoba, the annual economic burden of smoking is estimated to have been \$526 million in 2008 (\$170 million in direct costs – costs associated with health care; \$356 million in indirect costs – costs associated with morbidity and premature mortality).<sup>9</sup> In light of these high costs, it is important to recognize the cost effectiveness of tobacco use interventions. Numerous authors have identified that the reduction in costs of treating tobacco-related illness more than offsets the cost of cessation interventions,<sup>9-12</sup> with one study showing a better than 3-to-1 return on investment over a 16 year period.<sup>9</sup> Researchers have also demonstrated that cessation interventions are more cost-effective than other routinely used preventive interventions,<sup>10, 13</sup> such as treatment of hyperlipidemia in primary prevention of chronic disease and treatment of moderate to severe hypertension.<sup>12</sup>

In January 2011, an interprofessional, intersectoral WRHA Smoking Cessation Best Practice Working Group was established. The purpose of this group was:

- To facilitate the development and sustainable implementation of a WRHA-wide smoking cessation system that will promote consistent identification and effective intervention with people who use tobacco
- To effect practice change throughout acute care, long-term care, and community-based care so that a consistent level of quality in smoking cessation services is provided as a part of day-to-day services

A primary output of this Working Group was this ***Management of Tobacco Use and Dependence Regional Clinical Practice Guideline***.

## Goals and Objectives of the Guideline

The overarching goal of this document is to provide evidence-informed guidance for the assessment and management of tobacco use and dependence across all sectors and programs of the WRHA. More specifically:

- To recognize that tobacco use, and particularly tobacco dependence, is an addiction (a chronic, relapsing condition) that needs to be managed over the long-term
- To consistently identify patients/clients who are tobacco users
- To ensure prompt, appropriate, and consistent assessment and management of tobacco use and dependence, both for temporary abstinence from tobacco as well as for permanent cessation
- To inform the development of educational materials related to the management of tobacco use and dependence
- To decrease the prevalence of tobacco use within the WRHA
- To decrease the number of hospitalized patients who experience untreated nicotine withdrawal

## Target Population

This guideline targets the whole population who live or receive health services within the Winnipeg Health Region, in order to identify those who use tobacco. With respect to the management of tobacco use and dependence, this guideline specifically targets those who use tobacco in order to provide support to them and their families.

## Target Audience

This guideline was developed for use by all health care providers, including direct care staff, policy makers, educators and administrators. This guideline is applicable to all members of the interprofessional team.

## Key Definitions

### Abstinence

- voluntary restraint from using tobacco for a defined period of time (e.g. duration of hospitalization)

### Addiction

- a chronic, relapsing condition in which there is continued use of a substance or behavior in spite of evidence of negative effects

### Cessation

- process of discontinuing the use of tobacco products

### Health Care Provider

- refers to the broad range of health care professionals who work in a variety of settings, including acute care, primary care, home care, public health and long term care

### Patient/Client

- refers to those receiving services across diverse clinical settings where smoking cessation treatment and nicotine withdrawal management are provided, recognizing that some sectors have additional terms to identify recipients of service (e.g. resident, consumer, participant)

### Tobacco Use

- the practice of purposively using tobacco for its perceived physical and psychological benefits—e.g., mental alertness, relaxation, weight control. Repeated use often leads to addiction. Product may be taken into the body by inhaling the smoke from burning tobacco or by chewing a variety of smokeless tobacco products.<sup>14</sup>

### Tobacco Dependence

- an addiction to tobacco products caused by the drug nicotine and characterized by:
  - o Continued use despite knowledge of tobacco's harmful health effects
  - o Increasing tolerance to the substance
  - o Using up cigarette supply more quickly than intended
  - o Spending a good deal of time using the substance, including foregoing important activities because of smoking restrictions
  - o A well-defined withdrawal syndrome.<sup>15</sup>

## Guiding Principles

- To facilitate an appropriate response to tobacco use and dependence, it is necessary to recognize the addictive nature of tobacco
- Effective management of tobacco use and dependence requires a coordinated interdisciplinary approach, including collaboration with the patient/client in order to provide patient-centred care
- Recognize practice setting-specific needs and priorities
- Recognize and respect cultural differences with respect to tobacco use
- Frame the activities undertaken within a context of excellence in client care, patient safety, and integration

## Methodology

A thorough literature review of systematic reviews, meta-analyses and clinical practice guidelines<sup>16-24</sup> was the starting point for this process. This document is based on a compilation of published evidence regarding best practice in assessment and management of tobacco use and dependence as well as review and feedback from local expert opinion.

After conducting this review, the WRHA Smoking Cessation Best Practice Working Group (SCBPWG) decided to adopt the 2011 **Canadian Practice-Informed Smoking Cessation Guideline**,<sup>23</sup> developed by The Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment (CAN-ADAPTT), as the foundation of its recommendations. The rationale for this is:

- Literature reviewed for the development of CAN-ADAPTT Guideline encompasses literature reviewed by SCBPWG
- The CAN-ADAPTT Guideline is a Canadian product developed by interdisciplinary team, which included consultative processes
- It is the most recent of all published guidelines
- Recommendations in the CAN-ADAPTT Guideline are structured around the 5-A Model<sup>24</sup> for intervening with people who use tobacco
- Use of the CAN-ADAPTT Guideline allows for one evidence grading system (see Appendix A)

Part of the decision-making process was to compare the CAN-ADAPTT Guideline to the 2008 US Centre for Disease Control (CDC) Guideline,<sup>16</sup> which has generally been considered the gold- standard guideline for the treatment of tobacco use and dependence. These two guidelines were found to be very similar.

## How to Use This Guideline

This guideline is designed as a foundation that will support, rather than replace, the clinical judgment of health care providers. Some information in this guideline may be less applicable in certain situations, or with certain populations.

A number of sub-groups of the SCBPWG have developed evidence-based operational procedures and resources/tools to support implementation of this guideline and to provide context in the specific sectors and programs within the Region.

Please refer to Appendix A for description of grade of recommendation and level of evidence used by the CAN-ADAPTT Guideline.<sup>23</sup>

### **Recommendation #1: ASK**

Tobacco use status should be updated, for all patients/clients, by health care providers on a regular basis.

**Grade: 1A**

### **Recommendation #2: ADVISE**

Health care providers should clearly advise patients/clients to quit.

**Grade: 1C**

### **Recommendation #3: ASSESS**

Health care providers should assess the willingness of patients/clients to begin treatment to achieve abstinence/cessation.

**Grade: 1C**

### **Recommendation #4: ASSIST**

Every tobacco user who expresses the willingness to begin treatment to quit should be offered assistance.

**Grade: 1A**

a) Minimal interventions, of 1-3 minutes, are effective and should be offered to every tobacco user. However, there is a strong dose-response relationship between the session length and successful treatment, and so intensive interventions should be used whenever possible.

**Grade: 1A**

b) Counselling by a variety or combination of delivery formats (self-help, individual, group, helpline, web-based) is effective and should be used to assist patients/clients who express a willingness to quit.

**Grade: 1A**

c) Because multiple counselling sessions increase the chances of prolonged abstinence, health care providers should provide **four or more counselling sessions** where possible.

**Grade: 1A**

d) Combining counselling and smoking cessation medication is more effective than either alone, therefore both should be provided to patients/clients trying to stop smoking where feasible.

**Grade: 1A**

e) Motivational interviewing is encouraged to support patients'/clients' willingness to engage in treatment now and in the future.

**Grade: 1B**

f) Two types of counselling and behavioural therapies yield significantly higher abstinence rates and should be included in smoking cessation treatment:

- 1) providing practical counselling on problem solving skills or skill training and
- 2) providing support as part of treatment.

**Grade: 1B**

### **Notes:**

Acupuncture - Available evidence shows no difference in effectiveness



between active acupuncture and control acupuncture, suggesting any positive effect of acupuncture may be due to other factors such as expectations that the procedure will aid the cessation process.<sup>16, 25</sup>

Hypnosis, Laser Therapy – Available evidence is inadequate to determine effectiveness of these treatments.<sup>16, 23, 26</sup>

### **Recommendation #5: ARRANGE**

Health care providers:

a) should conduct regular follow-up to assess response, provide support and modify treatment as necessary.

**Grade: 1C**

b) are encouraged to refer patients/clients to relevant resources as part of the provision of treatment, where appropriate.

**Grade: 1A**

## **Recommendations Specific to Acute Care**

### **Recommendation #6**

All patients should be made aware of hospital smoke-free policies.

**Grade: 1C**

### **Recommendation #7**

All elective patients who smoke should be directed to resources to assist them to quit smoking prior to hospital admission or surgery, where possible.

**Grade: 1B**

### **Recommendation #8**

All hospitals should have systems in place to:

a) identify all smokers;

**Grade: 1A**

b) manage nicotine withdrawal during hospitalization;

**Grade: 1C**

c) promote attempts toward long-term cessation and;

**Grade: 1A**

d) provide/connect patients with follow-up support post-hospitalization.

**Grade: 1A**

### **Recommendation #9**

Pharmacotherapy should be considered:

a) to assist patients to manage nicotine withdrawal in hospital; and

**Grade: 1C**

b) for use in-hospital and post-hospitalization to promote long-term cessation.

**Grade: 1B**

It is important to note that this Guideline is intended for use across all sectors of the Region. The graded evidence used to support the acute care recommendations noted above was based on research in acute care settings, however the WRHA

considers the principles found in these recommendations applicable to all sectors of the Region. This means that health care providers across all sectors of the WRHA should inform patients/clients of smoke-free policies, identify all people who use tobacco, consider the use of pharmacotherapy for patients/clients to assist with management of nicotine withdrawal where appropriate, and to promote long-term cessation.

## Recommendations for Systems Change and Clinical Education

Clinical practice guidelines and other publications are consistent in their recommendations as they relate to systems change:

- A systematic approach to managing tobacco use and dependence is most effective for consistently identifying and intervening with tobacco users.<sup>16, 19, 23</sup> This can take the form of documentation tools, standing orders/order sets, EHR/EMR tools and prompts.
- All clinicians and clinicians-in-training should be trained in effective strategies to assist tobacco users willing to make a quit attempt and to motivate those unwilling to quit
- Training appears to be more effective when coupled with systems changes.<sup>16, 23</sup> Education should have consistent messaging, promote collaboration across the continuum of care, and across professions.<sup>23</sup>
- Sufficient resources should be allocated for systems support to ensure the delivery of efficacious tobacco use treatments.<sup>16, 19</sup>

## Medication Recommendations

The following medication recommendations are for use across all sectors of the Winnipeg Health Region. Some of the medications recommended are not available on the WRHA Acute Care Formulary and the WRHA Geriatrics and Long Term Care Formulary; all the medications are available for use in the community.

### Nicotine Replacement Therapy (NRT)

The dose of nicotine replacement should be made on the basis of the usual number of cigarettes smoked and titrated to effect. Table 1 below shows general dosing recommendations for NRT patch and gum based on the number of cigarettes typically smoked; however, clinical judgment for individual variation should always be used. Table 2 shows NRT lozenge dosing. Table 3 identifies clinical situations in which NRT use may be contraindicated, or where additional risk/benefit considerations may be needed prior to making a prescribing decision. Table 4 provides a summary of common drug interactions. Once a person has been established on an adequate NRT dose, this dose should be maintained for a minimum of 4 weeks, followed by a gradual tapering of dose (again titrating for adequate symptom management) until NRT use is discontinued. In some instances, particularly in patients with persistent and severe mental illnesses, NRT use may need to be considered for longer than the usual duration of 12 – 14 weeks in order to prevent relapse to tobacco use.

It should be noted that anyone receiving more than 21 mg nicotine patch, or patch with gum as needed, is being **prescribed NRT “off-label”**. This is becoming the practice norm for most persons who smoke more than 30 cigarettes per day, as the 21 mg patch does not adequately manage nicotine withdrawal for these persons.<sup>24, 27, 28</sup>

Historically, NRT was contraindicated if people were also using tobacco (i.e. if a person is smoking, she/he should not also use NRT). Health Canada now has approved NRT gum for a “reduce to quit” approach to smoking cessation. The aim is to reduce the number of cigarettes smoked per day, and replace some cigarettes with NRT gum. In fact, the risk of harm from cigarette smoking in conjunction with NRT use is minimal/non-existent- people tend to smoke and use NRT until they feel comfortable (i.e. until they have reached a therapeutically effective dose), and will stop smoking if they begin to experience symptoms of nicotine toxicity. Therefore, **concern that someone might smoke against medical advice while using NRT should not be a deterrent from prescribing NRT.**<sup>29, 30</sup>

**TABLE 1: GENERAL DOSING RECOMMENDATIONS\***

<b>Cigarettes per day (cpd)</b>	<b>NRT Patch*</b>	<b>NRT Gum*</b>
If patient smokes less than 10 cigarettes per day OR If patient weighs less than 45 kg	7 mg	2 mg one piece every 1-2 hours as needed (max: 15 pieces per day)
If patient smokes 10-20 cigarettes per day	14 mg	If using as monotherapy: 2 mg one piece every 1-2 hours as needed (max: 20 pieces per day)
If patient smokes 21-30 cigarettes per day	21 mg	If using as adjunct to patch: 2 mg one piece every 1-2 hours as needed (max: 15 pieces per day)
If patient smokes 31-40 cigarettes per day	28 mg (21 mg + 7 mg patch)	
If patient smokes greater than 40 cigarettes per day	42mg (21 mg patch x 2)	If using as monotherapy: 4 mg one piece every 1-2 hours as needed (max: 20 pieces per day)

\*NOTE: Dosing is based on using patch in combination with gum. The patch provides long-acting nicotine to manage nicotine withdrawal, and the gum is used as an adjunct to address withdrawal symptoms not managed by the patch. If patient requests gum only after understanding rationale for patch, order as per patient preference using monotherapy dosing.

The above dosing pertains to adults. Generally NRT use is avoided with adolescents, although clinical judgment needs to be used with individual adolescent patients.

## **NRT Gum – Prescribing Considerations**<sup>16</sup>

**Side Effects** – Common side effects include mouth soreness, hiccups, dyspepsia, and jaw ache. These effects are generally mild and transient and often can be alleviated by correcting the patient’s chewing technique.

**Chewing Technique** – Gum should be chewed slowly until a peppery or flavoured taste emerges, then “park” the gum between cheek and gum to facilitate nicotine absorption through the oral (buccal) mucosa. Gum should be slowly and intermittently chewed and parked for about 30 minutes or until taste dissipates.

**Absorption** – Acidic beverages (eg. coffee, juices, soft drinks) interfere with buccal absorption of nicotine, so eating and drinking anything except water should be avoided for 15 minutes before and during chewing.

**Dosing** – NRT is often not used in an adequate dose to obtain optimal clinical effects. Instructions to chew the gum on a fixed schedule (one piece q1-2h) may be more beneficial than ad lib use.

For hospitalized patients, consider leaving a small supply of gum at the bedside to ensure patient access to the medication when needed.

\*Patients who are recumbent, sedated, dysphagic, and/or obtunded should be evaluated to determine safety of NRT gum (risk of aspiration, not able to use appropriately). Patch alone may be indicated.  
Please refer to Table 4 below for common drug interactions with smoking cessation.

## **NRT Patch – Prescribing Considerations**<sup>16</sup>

**Location** – At the start of each day, the individual should place a new patch on a relatively hairless location, typically between the neck and waist, rotating the site to reduce local skin irritation.

**Activities** – No restrictions while using the patch.

**Dosing** – Patch should be applied upon waking on the quit day, and on each subsequent day. For those who experience sleep disruption, remove the 24-hour patch prior to bedtime.

**Skin Reactions** – Up to 50% of people using the nicotine patch will experience a local skin reaction. These are usually mild and self-limiting, but occasionally worsen with the course of therapy. Local treatment with hydrocortisone cream (0.5% or 1%) or triamcinolone cream (0.5%) and rotating patch sites may ameliorate such local reactions. In fewer than 5% of people, such reactions require the discontinuation of nicotine patch treatment.

Please refer to Table 4 below for common drug interactions with smoking cessation.

**TABLE 2: NRT LOZENGE DOSING**<sup>16</sup>

<b>Patient</b>	<b>Dose</b>	<b>Time</b>
If patient smokes first cigarette more than 30 minutes after waking	2 mg lozenge	Weeks 1 – 6 : one lozenge q 1-2h (Min. 9 / Max. 20 lozenges/day)
		Weeks 7 – 9 : one lozenge q 2-4 h
If patient smokes first cigarette within 30 minutes of waking	4 mg lozenge	Weeks 10 – 12 : one lozenge q 4-8h

### **NRT Lozenge – Prescribing Considerations**<sup>16</sup>

**Side Effects** – Common side effects include nausea, hiccups, headache, coughing and heartburn.

**Use** – The lozenge should be allowed to dissolve in the mouth rather than chewing or swallowing it.

**Absorption** – Acidic beverages (e.g. coffee, juices, soft drinks) interfere with buccal absorption of nicotine, so eating and drinking anything except water should be avoided for 15 minutes before and during use.

**Dosing** – Patients often do not use enough prn NRT to obtain optimal clinical effects. Instructions to use the lozenge on a fixed schedule (one piece q1-2h) may be more beneficial than ad lib use. For hospitalized patients, consider leaving a small supply of lozenges at the bedside to ensure patient access to the medication when needed.

\*Patients who are recumbent should be evaluated to determine safety of NRT lozenges (risk of aspiration, not able to use appropriately).

Please refer to Table 4 below for common drug interactions with smoking cessation.

### **NRT Oral Mist – Prescribing Considerations**<sup>29, 30</sup>

**Side Effects** – Tingling of the lips, hiccups, strong taste in mouth.

**Absorption** – Absorbed by the oral mucosa. Median time to maximum blood concentration is 10- 12 minutes, but starts within 60 seconds.

**Use** – Upon first use, prime the spray bottle by spraying it into the air until a fine mist appears. Point spray bottle into mouth and press down on spray bottle once, avoiding lips. A second spray should be given a few minutes after the first if cravings remain. Avoid spraying down the throat by not inhaling when spraying. Avoid swallowing for a few seconds after spraying.

**Dosing** – One or two sprays every 30-60 minutes as needed when cravings arise. Maximum dosing is 4 sprays per hour or 64 sprays per day.

Please refer to Table 4 below for common drug interactions with smoking cessation.

### **Nicotine Inhaler – Prescribing Considerations**<sup>16, 33</sup>

**Side Effects** – Local irritation in the mouth and throat, cough, and rhinitis. Side effects decline with continued use.

**Use** – Frequent, continuous puffing of the inhaler for 20 min should be undertaken. Delivery of nicotine declines significantly at temperatures below 4°C. In cold weather, the inhaler and cartridges should be kept in an inside pocket or other warm area.

**Absorption** – Acidic beverages (e.g. coffee, juices, soft drinks) interfere with buccal absorption of nicotine, so eating and drinking anything except water should be avoided for 15 minutes before and during use.

**Dosing** – A dose from the nicotine inhaler consists of a puff or inhalation. Each cartridge delivers 4 mg of nicotine over a total of 80 inhalations. Recommended dosage is 6-16 cartridges per day, for up to 6 months. Taper the dosage during the final 3 months of treatment.

Please refer to Table 4 below for common drug interactions with smoking cessation.

### **Considerations, Cautions, Contraindications of NRT Products**

Nicotine use is low risk for most healthy adults and the goal of NRT is to remove the exposure to harmful combustion products while withdrawing from nicotine addiction.

However, in some health conditions, nicotine itself poses or exacerbates health risks, particularly cardiovascular. Additionally, NRT use has not been well studied in some patient populations such as adolescents, frail elderly, and pregnant and breastfeeding women. In these situations, additional considerations and cautions should be applied; but in many if not most cases, NRT can and should still be used if that presents less risk than the alternative of continued tobacco use.

There are very few absolute contraindications to the use of NRT. In rare and specific clinical situations nicotine **is strongly contraindicated** through either patient tobacco use or nicotine replacement therapy.

More commonly, **relative contraindications** may occur which should be considered in comparison to the likelihood of continued tobacco use without NRT. If abstinence or cessation is achievable without NRT then that is preferred. However, if continued tobacco use is occurring or very likely to occur, clinical judgment should be used to achieve the lowest feasible nicotine risk.

In the past, NRT was too often withheld if there was even minimal concern about nicotine adverse effects. An overly cautious approach to nicotine prescribing can inadvertently result in higher patient nicotine exposure if withdrawal symptoms are self-medicated by continued tobacco use instead of NRT.

Below is a summary of absolute and relative contraindications for NRT. Table 3 provides additional clinical considerations within key service areas. Table 4 summarizes common drug interactions with smoking and cessation. **These resources are intended to assist the individual clinical judgment that is needed to achieve the lowest tobacco and nicotine exposure possible for every patient.**

### **Absolute Contraindications**

- All free flap patients: NRT and tobacco products must not be used by these patients for at least 2 weeks before and 2 weeks after free flap surgery. For planned procedures involving face and breast, tobacco and NRT use should be avoided 4 weeks before and 4 weeks after surgery. The plastic surgeon managing the patient should decide the timing of NRT.<sup>34-36, 47</sup>
  
- Patients who due to the severity of illness and circumstances of care do not have the option to use tobacco products (i.e. would not be otherwise exposed to nicotine if not prescribed NRT) and are comfortable without NRT and:
  - o are in the immediate (within 2 weeks) post myocardial infarction period<sup>16</sup> or
  - o have serious arrhythmias or
  - o have unstable angina pectoris<sup>16</sup> or
  - o are hemodynamically or electrically unstable<sup>37-41</sup> or
  - o have had orthopedic surgery or a serious fracture(s).<sup>42-45</sup>

### **Relative Contraindications**

Patients who may continue to use tobacco if not prescribed NRT but:

- are in the immediate (within 2 weeks) post myocardial infarction period<sup>16</sup> or
- have serious arrhythmias or



- have unstable angina pectoris<sup>16</sup> or
- are hemodynamically or electrically unstable<sup>37-41</sup> or
- have had orthopedic surgery or serious fractures.<sup>42-45</sup>

Abstinence without NRT is preferred, but NRT may be safer than continued use of tobacco in the above circumstances - individual clinical judgment required.

### **Cautions**

- Women who are pregnant or breastfeeding  
Abstinence or cessation without NRT is preferred since NRT in pregnant and lactating women has not been well studied. However, NRT is safer than continued use of tobacco in the above circumstances - individual clinical judgment required<sup>46</sup>. Shorter-acting forms of NRT (i.e. gum, lozenge, inhaler, mist) are preferred over the longer-acting NRT patch as a means of reducing fetal exposure to nicotine.
- Adolescents  
Although nicotine replacement has been shown to be safe in adolescents, there is little evidence that NRT is effective in promoting long-term abstinence among adolescent smokers<sup>16</sup>. Abstinence or cessation without NRT is preferred. For some physically mature youth who are continuing to use tobacco despite attempts to support them to be abstinent or quit without NRT, NRT can be considered.

**TABLE 3: NRT USE - CLINICAL CONSIDERATIONS**

<b>SERVICE AREA</b>	<b>KEY CLINICAL CONSIDERATIONS</b>
Anesthesia	<ul style="list-style-type: none"> <li>• General prescribing guidelines can be followed, and following fasting guidelines where required.</li> </ul>
Child Health/Adolescent Medicine	<ul style="list-style-type: none"> <li>• NRT is safe in adolescents but little evidence for long-term cessation.</li> <li>• NRT use has not been studied in children.</li> <li>• Generally NRT use is avoided with adolescents, but clinical judgment needs to be used with individual adolescent patients.</li> <li>• For some physically mature youth who are continuing to use tobacco despite attempts to support them to be abstinent or quit without NRT, NRT can be considered.</li> </ul>
Cardiac	<ul style="list-style-type: none"> <li>• NRT is safe and effective in smokers with stable coronary artery disease.</li> <li>• NRT may be used in hospitalized patients with acute coronary syndromes when necessary; however, NRT should be used with caution among particular cardiovascular patient groups:               <ul style="list-style-type: none"> <li>○ those in the immediate (within 2 weeks) post myocardial infarction period,</li> <li>○ those with serious arrhythmias and</li> <li>○ those with unstable angina pectoris</li> </ul> </li> </ul>
Critical Care	<ul style="list-style-type: none"> <li>• Use in critical care units should be determined on an individual patient basis rather than routinely ordered.</li> </ul>

	<ul style="list-style-type: none"> <li>• Due to the severity of illness, critical care patients do not generally have the option to use tobacco products against advice, so the risk of NRT is not relative to continued (and higher risk) tobacco use.</li> <li>• Critical care patients often have reduced consciousness due to illness or sedation so may experience less nicotine withdrawal symptoms.</li> <li>• Select subgroups of patients may benefit from NRT, such as those with restlessness refractory to usual management.</li> <li>• NRT use will be considered on the daily goals sheet in situations where NRT may be helpful.</li> </ul>
Delirium, Dementia	<ul style="list-style-type: none"> <li>• Safety of NRT in the setting of delirium or dementia has not been studied.</li> <li>• Nicotine withdrawal may contribute to agitation in delirious or demented patients. In the appropriate setting, consider the cautious use of NRT in agitated, cognitively impaired patients who were recent smokers and who have no other apparent cause of agitation.</li> <li>• Continued smoking significantly limits the choice of Personal Care Home. Advise patients and families about the pros and cons of smoking cessation when paneling for PCH.</li> </ul>
Emergency	<ul style="list-style-type: none"> <li>• For most patients, general prescribing guidelines can be followed.</li> <li>• If differential diagnosis includes conditions associated with relative contraindications (eg. cardiac) the applicable considerations should be followed.</li> </ul>
Frail Elderly	<ul style="list-style-type: none"> <li>• Dose response has not been studied.</li> <li>• Depending on life expectancy, long term benefits of smoking cessation (cancer, COPD prevention) may not be relevant. Short term benefits may well make cessation worthwhile (improvement in cardiovascular symptoms and outcomes).</li> <li>• Consider starting NRT at lower doses in frail, low-body-mass elderly. Increase to usual doses if nicotine withdrawal symptoms persist.</li> </ul>
General Surgery	<ul style="list-style-type: none"> <li>• For most patients, general prescribing guidelines can be followed.</li> <li>• If differential diagnosis includes conditions associated with contraindications (such acute MI or serious arrhythmia) the applicable considerations should be followed.</li> </ul>
Internal Medicine	<ul style="list-style-type: none"> <li>• NRT should be routinely offered to all patients who smoke and are admitted to respiratory medicine, internal medicine and coronary care units unless there are specific contraindications.</li> <li>• Patients who are hemodynamically or electrically unstable should have NRT deferred until</li> </ul>



	<p>stabilized and off vasopressors and/or inotropes.</p> <ul style="list-style-type: none"> <li>• If differential diagnosis includes conditions associated with relative contraindications (eg. cardiac) the applicable considerations should be followed.</li> </ul>
Mental Health/Psychiatry (15)	<ul style="list-style-type: none"> <li>• The use of NRT is safe for patients/clients with mental illnesses.</li> <li>• Patients/clients can smoke while using NRT.</li> <li>• Combination therapy (i.e. patch and gum simultaneously) can be used.</li> <li>• If the patient/client reports nightmares, remove the patch at night.</li> <li>• Patients/clients with mental illness often engage in high levels of smoking and therefore may require higher dose of NRT. Exceeding the usual maximum dose (i.e. double patching) and duration requires cautious titration upwards and consultation with pharmacy.</li> <li>• Maintenance (<math>\geq 10</math> weeks) may have some benefit but must be considered on the individualized basis.</li> <li>• There are several psychotropic drugs whose levels are increased with smoking cessation/abstinence (in particular, Clozapine).</li> <li>• More frequent monitoring of serum levels of these medications is advised.<sup>48</sup></li> </ul>
Orthopedic Surgery	<ul style="list-style-type: none"> <li>• Non-nicotine cessation medications and/or cessation counselling should be routinely offered to all orthopaedic inpatients who use tobacco. Abstinence or cessation should be attempted without the use of NRT if at all possible.</li> <li>• Nicotine markedly increases complications of fractures, especially non-union.<sup>42-45</sup></li> <li>• Trauma patients confined to bed do not generally have the option to use tobacco products against advice, so the risk of NRT is not relative to continued (and higher risk) tobacco use.</li> <li>• If orthopaedic patients not confined to bed are continuing to use tobacco products, the lesser risk of NRT could be considered with the goal being to achieve the lowest possible exposure to nicotine.</li> </ul>
Plastic Surgery	<ul style="list-style-type: none"> <li>• Given the complexity of plastic surgery and reconstructive procedures, NRT should always be a deliberate decision by the plastic surgeon as to when it can be safely used. This includes the preoperative phase of care as some authors recommend abstinence from nicotine (both tobacco and NRT use) for at least 4 weeks prior to planned plastic surgical procedures.</li> <li>• All free flap patients must stop smoking before surgery; they are advised that one cigarette may cause flap necrosis. NRT and tobacco products</li> </ul>

	<p>must not be used by these patients for at least 2 weeks before and 2 weeks after free flap surgery. For planned procedures involving face and breast, tobacco and NRT use should be avoided 4 weeks before and 4 weeks after surgery.<sup>47</sup></p> <ul style="list-style-type: none"> <li>• Smokers who stop smoking for 4 weeks prior to reduction mammoplasty have similar complication rates to non-smokers.<sup>49</sup></li> <li>• Smokers who stop smoking for 3 weeks prior to Head and Neck Reconstructive surgery have similar wound healing to non-smokers.<sup>50</sup></li> <li>• The face lift operation is an excellent model of flap surgery. A face lift patient who smokes is 12.46 X more likely to suffer skin sloughing than a non-smoker.<sup>36</sup></li> </ul>
Vascular Surgery	<ul style="list-style-type: none"> <li>• General prescribing guidelines can be followed</li> <li>• <b>Note</b> – particular emphasis on smoking abstinence and/or cessation with vascular patients is warranted due to the detrimental effects of smoking on bypass graft patency rates, abdominal aortic aneurysm (AAA) growth, and amputation rates compared to non-smokers.</li> </ul>
Women's Health	<ul style="list-style-type: none"> <li>• Women who are pregnant and smoke should be encouraged to stop tobacco use without medication.</li> <li>• Nicotine patch and gum have not been studied adequately in women who are pregnant and smoke.</li> <li>• Nicotine patch and gum have also not been evaluated in breastfeeding patients.</li> <li>• NRT, especially short-acting NRT (i.e. gum, lozenge, inhaler), is safer than smoking for the pregnant woman and the fetus if she is unable to stop smoking with a behavioural intervention.<sup>46</sup></li> <li>• A discussion regarding the risks and benefits of any form of nicotine to the developing fetus should be had with the patient. It should be stressed that NRT removes the risk of other highly toxic chemicals from the developing fetus.<sup>46</sup></li> </ul>

## TABLE 4: TABLE OF COMMON DRUG INTERACTIONS WITH SMOKING AND CESSATION

### Potential drug interactions with smoking and quitting

(Current as of September 2011)

Many drug interactions have been reported with cigarette smoking.<sup>1-4</sup> Smoking induces drug metabolizing enzymes (primarily CYP1A2) in the liver. As a result, smokers have higher clearance of certain drugs and require higher doses to achieve clinical response. Conversely, when smokers quit smoking, their induced enzyme levels revert to normal. This may result in toxic drug levels in these patients whose drug doses were established while smoking.

Some potential drug interactions associated with cigarette smoking and quitting are depicted below. Although available information was based on case reports and small studies, clinicians should be aware of such potentials and monitor their patients closely for drug efficacy and toxicity.

Drug	Reported effects of smoking	Possible strategies after smoking cessation*
caffeine <sup>1,3</sup>	<ul style="list-style-type: none"> <li>↑ clearance (by 56%)</li> </ul>	<ul style="list-style-type: none"> <li>Assess total caffeine intake from all sources; ↓ intake by half; monitor for caffeine toxicity (e.g., irritability &amp; insomnia)</li> </ul>
clozapine <sup>5,6</sup>	<ul style="list-style-type: none"> <li>↓ plasma concentrations (by 18%)</li> </ul>	<ul style="list-style-type: none"> <li>Monitor for clozapine toxicity; ↓ dose (by a factor of 0.5) may be required</li> </ul>
flecainide <sup>1,4</sup>	<ul style="list-style-type: none"> <li>↑ clearance (by 61%), ↓ trough serum concentrations (by 25%); ↑ dose requirements (by 17%)</li> </ul>	<ul style="list-style-type: none"> <li>May need to ↓ dose, but no specific recommendation available. Monitor for clinical response</li> </ul>
fluvoxamine <sup>1,4,7</sup>	<ul style="list-style-type: none"> <li>↑ clearance (by 24%), ↓ AUC (by 31%), ↓ C<sub>max</sub> (by 32%), ↓ C<sub>ss</sub> (by 12-39%)</li> </ul>	<ul style="list-style-type: none"> <li>Dosage adjustment not routinely recommended; close monitoring for adverse events</li> </ul>
insulin <sup>1,3,4</sup> (subcutaneous)	<ul style="list-style-type: none"> <li>↑ insulin requirement possible due to nicotine-induced insulin resistance &amp; vasoconstriction (i.e., ↓ adsorption)</li> </ul>	<ul style="list-style-type: none"> <li>Close monitoring of blood glucose, especially for patients prone to hypoglycemia or when tight glucose control is needed</li> </ul>
mexiletine <sup>1,4,8</sup>	<ul style="list-style-type: none"> <li>↑ oral clearance (by 25%); ↓ t<sub>1/2</sub> (by 36%)</li> </ul>	<ul style="list-style-type: none"> <li>May need to ↓ dose, but no specific recommendation available. Monitor for clinical response. Use caution with older adults</li> </ul>
olanzapine <sup>1,3,5</sup>	<ul style="list-style-type: none"> <li>↑ clearance (by 98%), ↓ plasma levels (by 12%)</li> </ul>	<ul style="list-style-type: none"> <li>May need to ↓ dose, but no specific recommendation available. Monitor for excessive adverse effects</li> </ul>
propranolol <sup>1,4</sup>	<ul style="list-style-type: none"> <li>↑ clearance (by 77%)</li> </ul>	<ul style="list-style-type: none"> <li>Blood levels may ↑ but clinical implication is unclear due to wide dosage range; closely monitor for adverse events</li> </ul>
theophylline <sup>1,4</sup>	<ul style="list-style-type: none"> <li>↑ clearance (by 58-100%); ↓ t<sub>1/2</sub> (by 63%); ↑ volume of distribution (by 31%)</li> </ul>	<ul style="list-style-type: none"> <li>Monitor levels and adjust dose accordingly; ↓ dose (by 25-33%) may be needed to maintain therapeutic drug levels</li> </ul>
warfarin <sup>1,4</sup>	<ul style="list-style-type: none"> <li>INR prolongation has been reported</li> </ul>	<ul style="list-style-type: none"> <li>Closely monitor INRs; ↓ dose (by 14-23%) may be needed</li> </ul>

\*The relationship between the amount of cigarette smoking and the extent of drug interaction is unclear. The information in the table is based on current available literature and should not replace sound clinical judgments. Dosages should be individualized to achieve optimal therapeutic response with minimal toxicities. Abbreviations: AUC area under concentration-time curve; C<sub>max</sub> peak concentrations; C<sub>ss</sub> steady-state concentrations; t<sub>1/2</sub> half-life

#### REFERENCES

1. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. *Clin Pharmacokinet* 1999;18:53,62,xii.
2. Kroon LA. Drug interactions and smoking; raising awareness for acute and critical care providers. *Crit Care Nurs Clin North Am* 2006;18:1533-40
3. Kroon LA. Drug interactions with smoking. *Am J Health Syst Pharm* 2007;64:1917-21.
4. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation; potentially risky effects on prescribed medication. *J Clin Nurs* 2009;18:1533-40.
5. deLeon J. Psychopharmacology. Atypical antipsychotic dosing: the effect of smoking and caffeine. *Psychiatr Serv* 2004;55:491-3
6. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. *Psychopharmacology (Berl)* 1989;99 Suppl.:S38-S40
7. Spigset O, Carborg L, Hedenmalm K, Dahqvist R. Effects of cigarette smoking on fluvoxamine pharmacokinetics in humans. *Clin Pharmacol Ther* 1995;58:339-403
8. Grech-Belanger O, Gilbert M, Turgeon J, LeBlanc PP. Effect of cigarette smoking on mexiletine kinetics. *Clin Pharmacol Ther* 1989;37:638-43.

Note: INR = International Normalized Ratio, a blood test measuring the time it takes for blood to clot and comparing it to an average. Copyright © Province of British Columbia. All rights reserved. Reprinted with permission of the Province of British Columbia. [www.ipp.gov.bc.ca](http://www.ipp.gov.bc.ca)

## **Non-Nicotine Medication Recommendations**

Both bupropion SR (Zyban) and varenicline (Champix) are prescription medications which can double or triple the likelihood of long-term abstinence from tobacco use compared to placebo. The possible mechanisms of action for bupropion include blockade of neuronal re-uptake of dopamine and norepinephrine and blockade of nicotinic acetylcholinergic receptors. The presumed mechanism of action for varenicline is partial nicotine receptor agonist and antagonist effects.<sup>16</sup>

### **Bupropion SR (Zyban) – Prescribing Considerations**

**Side Effects** – Headache, insomnia, weight loss and dry mouth.<sup>16, 51</sup>

If insomnia is marked, take the PM dose earlier in the afternoon, but at least 8 hours after the first daily dose.<sup>16</sup>

**Dose** – Begin bupropion SR treatment 1-2 weeks before stopping cigarette use.

Starting dose is 150 mg every morning for three days, which is increased to 150 mg twice daily for 7-12 weeks. Long term therapy is required in some individuals for up to 6 months.<sup>16</sup>

**Pregnancy** – Bupropion SR has not been shown to be effective as a therapy for treating tobacco dependence in pregnant smokers. In addition it has not been evaluated in breastfeeding patients.<sup>16</sup>

### **Contraindications**<sup>16, 51</sup>

Bupropion SR is contraindicated in the following individuals:

- history of seizure disorder
- history of eating disorder
- those taking another form of bupropion
- those who have used an MAO inhibitor in the past 14 days
- those who have undergone abrupt discontinuation of ethanol or sedatives
- hypersensitivity to Bupropion SR in the past

### **Cautions**

Reports of increased rates of depressed mood, agitation, changes in behaviour, suicidal thoughts and behaviour while using Bupropion SR exist. Clinicians should elicit a psychiatric history prior to using this medication and monitor any changes in mood and behaviour during use.<sup>51</sup>

Hypertension has been reported in some individuals using bupropion alone or in combination with nicotine transdermal systems.<sup>16, 51</sup>

Reduced dose and/or frequency is recommended in those with hepatic impairment.<sup>51</sup> Consider a reduction in dosing frequency for those with renal impairment.<sup>51</sup>

Use alcohol only in moderation.<sup>51</sup>

### **Varenicline (Champix) - Prescribing Considerations**<sup>16</sup>

**Side Effects** – Nausea, insomnia, abnormal dreams.

For those with gastrointestinal upset, consider taking medication after eating or with a large glass of water.

For those with insomnia, consider taking medication earlier in the day.

**Dose** – Begin therapy one week before quit date at 0.5 mg once daily for three days, followed by 0.5 mg twice daily for 4 days, followed by 1 mg twice daily for 3 months.

May use for up to six months. For those who experience side effects, consider reduced

dosage (0.5 mg twice daily).

**Pregnancy** – Varenicline has not been shown to be effective as a therapy for treating tobacco dependence in pregnant smokers. In addition it has not been evaluated in breastfeeding patients.

**Contraindications**

Known history of hypersensitivity or severe skin reactions to varenicline.<sup>52</sup>

**Cautions**

Reports of increased rates of depressed mood, agitation, changes in behaviour, suicidal thoughts and behaviour exist with use of varenicline. Clinicians should elicit a psychiatric history prior to using this medication and monitor any changes in mood and behaviour during use.<sup>16, 52</sup>

From the information available to date, it is not possible to determine whether varenicline increases the risk of heart or stroke events in people who have cardiovascular disease.<sup>52, 53</sup>

Use with caution in those with kidney disease or who are on dialysis. A reduced dose is recommended in these patients.<sup>16</sup>

Patients may experience an impairment of the ability to drive or operate heavy machinery.<sup>16</sup> Alcohol may enhance the adverse effects of varenicline, including psychiatric events. Use alcohol only in moderation.<sup>52</sup>

## References

1. Canadian Tobacco Use Monitoring Survey (2010). [http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/\\_ctums-esutc\\_2010/ann-eng.php#t2](http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_2010/ann-eng.php#t2)
2. WRHA (2010). Winnipeg Regional Health Authority Community Health Assessment, 2009-2010. Winnipeg.
3. Baliunas D, Patra J, Rehm J, Popova S, Kaiserman M, & Taylor B (2007). Smoking-attributable mortality and expected years of life lost in Canada 2002: Conclusions for prevention and policy. *Chronic Diseases in Canada*, 27(4), 154-62.
4. Lasser K, Boyd JW, Woolhandler S, Himmelstein, DU, McCormick D, & bor DH (2000). Smoking and mental illness: A population-based prevalence study. *The Journal of the American Medical Association*, 284(20), 2606-10.
5. Zideonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun PS, & Riley WT (2008). Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine & Tobacco Research* 10(12), 1691-1715.
6. Canadian Tobacco Use Monitoring Survey (2010). [http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/\\_ctums-esutc\\_2010/ann-eng.php#t8](http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_2010/ann-eng.php#t8)
7. Health Canada, First Nations, Inuit and Aboriginal Health <http://www.hc-sc.gc.ca/fniah-spnia/substan/tobac-tabac/index-eng.php>
8. Martens P, Bartlett J, Burlan E, Prior H, Burchill C, Huq S, Romphf L, Sanguins J, Carter S & Bailly A (2010). Profile of Metis health status and healthcare utilization in Manitoba: A population- based study. Manitoba Centre for health Policy in collaboration with the Manitoba Métis Federation, June 2010. Winnipeg.
9. Heart & Stroke Foundation Manitoba (2010). Making the case for primary prevention: An economic analysis of risk factors in Manitoba. Winnipeg.
10. Kahn R, Robertson RM, Smith R, & Eddy D (2008). The impact of prevention on reducing the burden of cardiovascular disease. *Circulation*, 118: 576-85.
11. Lightwood J (2003). The economics of smoking and cardiovascular disease. *Progress in Cardiovascular Diseases*, 46(1), 39-78.

12. Benowitz NL (2003). Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment. *Progress in Cardiovascular Diseases*, 46(1), 91-111.
13. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, & Baker T (1997). Cost-effectiveness of the Clinical Practice Recommendations in the AHCPR Guideline for Smoking Cessation. *JAMA*, 278: 1759-66.
14. Mosby Elsevier (2008). *Mosby's Dental Dictionary, 2nd edition*. St. Louis, MO: Mosby Elsevier.
15. American Psychiatric Association (2000). *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)*. Arlington, VA: American Psychiatric Association.
16. Fiore MC, Jaen CR, Baker TB, et al (2008). *Treating Tobacco Use and Dependence: 2008 Update*. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. [http://www.surgeongeneral.gov/tobacco/treating\\_tobacco\\_use08.pdf](http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf)
17. O'Donnell DE, Aaron S, Bourbeau J, et al (2007). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Canadian Respiratory Journal*, 14(Suppl B):5B-32B.
18. O'Donnell DE, Hernandez P, Kaplan A, et al (2008). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. *Canadian Respiratory Journal*, 15(Suppl A):1A-8A.
19. Registered Nurses Association of Ontario (2007). *Integrating Smoking Cessation into Daily Nursing Practice*. Toronto, Canada: Registered Nurses Association of Ontario. <http://www.tobaccofreernao.ca/en/resources/best-practices-guidelines/integrating-smoking-cessation-daily-nursing-practice-summary-rec>
20. Rice VH, Stead LF (2008). Nursing interventions for smoking cessation. *Cochrane Database of Systematic Reviews*, Issue 1. Art. No.: CD001188. DOI: 10.1002/14651858.CD001188.pub3.
21. Rigotti NA, Munafò MR, Stead LF (2007). Interventions for smoking cessation in hospitalized patients. *Cochrane Database of Systematic Reviews*, Issue 3. Art. No.: CD001837. DOI: 10.1002/14651858.CD001837.pub2.
22. NICE (March 2006) Public health intervention guidance no.1 – Brief interventions and referral for smoking cessation in primary care and other settings. [http://www.nice.org.uk/nicemedia/pdf/PH001\\_smoking\\_cessation.pdf](http://www.nice.org.uk/nicemedia/pdf/PH001_smoking_cessation.pdf)



23. CAN-ADAPTT (2011). *Canadian Practice-Informed Smoking Cessation Guideline*. Toronto, Canada: Canadian Action Network for the Advancement, Dissemination and Adoption of Practice- informed Tobacco Treatment, Centre for Addiction and Mental Health.
24. Fiore MC, Bailey WC, Cohen SJ, et al (2000). *Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation*. US Department of Health and Human Services, Public Health Service.
25. White AR, Rampes H, LiuJP, Stead LF, Campbell J. Acupuncture and related interventions for smoking cessation. *Cochrane Database of Systemic Reviews* 2011 Jan 19;(1):CD000009. doi: 10.1002/14651858.CD000009.pub3.
26. Barnes J, Dong CY, McRobbie H, Walker N, Mehta M, Stead LF. Hypnotherapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2010, Issue 10. Art. No.: CD001008. DOI: 10.1002/14651858.CD001008.pub2.
27. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2012, Issue 11. Art. No.: CD000146. DOI: 10.1002/14651858.CD000146.pub4.
28. Shah et al (2008). Systematic review and meta-analysis of combination therapy for smoking cessation. *Journal of the American Pharmacists Association*, 48(5), 659-65.
29. Silagy C, Lancaster T, Stead L, Mant D, Fowler, G (2004). Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2004, Issue 3. Art. No.: CD000146. DOI:10.1002/14651858.CD000146.pub2.,
30. Hughes, JR, Adams, EH, Franzon, MA, Maguire, MK, Guary, J. A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler. *Tobacco Control*, 2005; 14: 49-54.
31. Nicorette. Nicorette Quickmist. 2012; Available at: <http://www.nicorette.ca/stop-smoking/products/quickmist>. Accessed 09 Sept 2012.
32. Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. *Nicotine Tob Res* 2011 Dec;13(12):1176-1182.
33. Lexidrugs. Nicotine: Drug Information. 2012; Available at: [http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/nicotine-drug-information?source=search\\_result&search=nicotine&selectedTitle=1%7E150](http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/nicotine-drug-information?source=search_result&search=nicotine&selectedTitle=1%7E150). Accessed 09 Sept 2012.



34. Ely PB, Kobayashi LA, Campos JHO, Gomes HC, Juliano Y, Gerreira LM (2009). Nicotine on rat TRAM flap: *Acta Cir Bras* [online]. vol.24, n.3, pp. 216-220. ISSN 1678-2674. <http://dx.doi.org.proxy2.lib.umanitoba.ca/10.1590/S0102-86502009000300010>.
35. Forrest CR, Pang CY, Lindsay WK (1991). Pathogenesis of ischemic necrosis in random pattern skin flaps induced by long-term low-dose nicotine treatment in the rat. *Plast Reconstr Surg*;87(3):518-28.
36. Rees TD, Liverett DM, Guy CL (1984). The effect of cigarette smoking on skin flap survival in the face lift patient. *Plast Reconstr Surg* 1984; 73(6) 911-5.
37. Cartin-Ceba R, Warner DO, Hays JT, Afessa B (2011). Nicotine replacement therapy in critically ill patients: a prospective observational cohort study; *Critical Care Medicine*; July;39(7);1635-40.
38. Lucidarme O, Seguin A, Daubin C, Ramakers M, Terzi N, Beck P, Charbonneau P, du Cheyron D (2010). Nicotine withdrawal and agitation in ventilated critically ill patients. *Crit Care*;14(2)R58.
39. Seder DB, Schmidt JM, Badjatia N, Fernandez L, Rincon F, Claassen J, Gordon E, Carrera E, Kurtz P, Lee K, Connolly ES, Mayer SA (2011). Transdermal nicotine replacement therapy in cigarette smokers with acute subarachnoid hemorrhage. *Neurocrit Care*; February;14(1):77-83.
40. Lee AH, Afessa B (2007). The association of nicotine replacement therapy with mortality in a medical intensive care unit. *Critical Care Medicine*;June;35(6)1517-21.
41. Najem B, Houssiere A, Pathak A, Janssen C, Lemogoum D, Xhaet O, Cuylits N, van de Borne P (2006). Acute Cardiovascular and sympathetic effects of nicotine replacement therapy. *Hypertension*;2006;47;1162-67.
42. Moghaddam A, Weiss S, Wöfl CG, Schmeckenbecher K, Wentzensen A, Grütznier PA, Zimmermann G (2010). Cigarette smoking decreases TGF- $\beta$ 1 serum concentrations after long bone fracture. *Injury*; 41(10):1020-5.
43. Krannitz KW, Fong HW, Fallat LM, Kish J (2009). The effect of cigarette smoking on radiographic bone healing after elective foot surgery. *The Journal of Foot and Ankle Surgery*. 48(5):525-7.
44. Little CP, Burston BJ, Hopkinson-Woolley J, Burge P (2006). Failure of surgery for scaphoid non-union is associated with smoking. *J Hand Surg Br*. 31(3):252-5.
45. Raikin SM, Landsman JC, Alexander VA, Froimson MI, Plaxton NA (1998). Effect of

nicotine on the rate and strength of long bone fracture healing: *Clin Orthop Relat Res*:August; (353):231-7.

46. Ontario Medical Association (2008). OMA Position Paper: Rethinking Stop-Smoking Medications: Treatment Myths and Medical Realities (Jan.08) Toronto, ON. Available at:  
<https://www.oma.org/Resources/Documents/e2008RethinkingStop-SmokingMedications.pdf>
47. Krueger JK & Rohrich RJ (2001). The scientific rationale for tobacco abstinence in plastic surgery. *Plast Reconstr Surg*; 108(4); 1063-73.
48. Meyer JM (2001). Individual changes in clozapine levels after smoking cessation: results and a predictive model. *Journal of Clinical Psychopharmacology* 21(6):569-74.
49. Chan LKW, Withey S & Butler PEM (2006). Smoking and wound healing problems in reduction mammoplasty: Is the introduction of urine nicotine testing justified? *Ann Plast Surg*; 56(2): 111-5.
50. Kuri M, Nakagawa M, Tanaka H, Hasuo S & Kishi Y (2005). Determination of the duration of preoperative smoking cessation to improve wound healing after head and neck surgery. *Anesthesiology*; 102(5):892-6.
51. Lexidrugs. Bupropion: Drug Information. 2012; Available at:  
[http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/bupropion-drug-information?source=search\\_result&search=bupropion&selectedTitle=1%7E88](http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/bupropion-drug-information?source=search_result&search=bupropion&selectedTitle=1%7E88).  
Accessed 09 Sept 2012.
52. Lexidrugs. Varenicline: Drug Information. 2012; Available at:  
[http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/varenicline-drug-information?source=search\\_result&search=varenicline&selectedTitle=1%7E22](http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/varenicline-drug-information?source=search_result&search=varenicline&selectedTitle=1%7E22).  
Accessed 09 Sept 2012.
53. Pfizer Canada. Champix Product Monograph (14 Dec 2011). Available at:  
[www.pfizer.ca/en/our\\_products/products/patient\\_infosheet/152](http://www.pfizer.ca/en/our_products/products/patient_infosheet/152) Accessed 24 Oct 2012.

## Appendix A

Grade of Recommendation & Level of Evidence Summary Table for CAN-ADAPTT Summary Statements

GR/LOE*	CLARITY OF RISK/BENEFIT	QUALITY OF SUPPORTING EVIDENCE	IMPLICATIONS
<b>1A</b> Strong Recommendation <i>High Quality Evidence</i>	Benefits clearly outweigh risk and burdens, or vice versa	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.	Strong recommendations, can apply to most patients in most circumstances without reservation. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.
<b>1B</b> Strong Recommendation <i>Moderate Quality Evidence</i>	Benefits clearly outweigh risk and burdens, or vice versa	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.	Strong recommendation and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.
<b>1C</b> Strong Recommendation <i>Low Quality Evidence</i>	Benefits appear to outweigh risk and burdens, or vice versa	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.	Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality.
<b>2A</b> Weak Recommendation <i>High Quality Evidence</i>	Benefits closely balanced with risks and burdens	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.	Weak recommendation, best action may differ depending on circumstances or patients or societal values
<b>2B</b> Weak Recommendation <i>Moderate Quality Evidence</i>	Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.	Weak recommendation, alternative approaches likely to be better for some patients under some circumstances
<b>2C</b> Weak Recommendation <i>Low Quality Evidence</i>	Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.	Very weak recommendation; other alternatives may be equally reasonable.

\* GR- Grade of Recommendation, LOE – Level of Evidence

\*\* Adapted from: UpToDate. Grading guide. No date. Available from: <http://www.uptodate.com/home/about/policies/grade.html>; and Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians task force. *Chest*. 2006 Jan;129(1):174-81, originally adapted from the GRADE Working Group.